CurrentPremera BluecrossPolicy 8.01.17

Hematopoietic Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome

Defines when autologous, tandem, reduced-intensity allogeneic, and myeloablative allogeneic hematopoietic cell transplants are considered medically necessary or investigational for multiple myeloma and POEMS syndrome for Premera BlueCross members and their providers.

Policy Summary

PayerPremera Bluecross

PolicyHematopoietic Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome

Policy CodePolicy 8.01.17

Change TypeNo material clinical or coverage changes

Effective DateApr 1, 2026

Next Review DateApr 1, 2026

Key ActionObtain preauthorization and provide documentation showing medical necessity criteria are met, including diagnosis, disease severity, and prior treatments.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

coveredautologous HCT

conditionaltandem autologous HCT

investigationalallogeneic HCT

codescoding list

multipleguideline citations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations and Medical Necessity Criteria

Medical Necessity and Investigational Determinations

Covered when the specific medical necessity conditions below are met:

Autologous HCT for Multiple Myeloma: A single or second (salvage) autologous hematopoietic cell transplantation may be considered medically necessary to treat multiple myeloma.

from Policy Coverage Criteria

Tandem autologous HCT for Multiple Myeloma: Tandem autologous hematopoietic cell transplantation may be considered medically necessary for individuals who fail to achieve at least a near-complete or very good partial response after the first transplant in the tandem sequence.must fail to achieve near-complete or very good partial response

see Additional Information for response definitions

Autologous HCT for POEMS: Autologous hematopoietic cell transplantation may be considered medically necessary to treat disseminated POEMS syndrome.disseminated POEMS

see Additional Information re: disseminated disease

Allogeneic HCT for MM and POEMS: Allogeneic hematopoietic cell transplantation, myeloablative or nonmyeloablative, as initial therapy of newly diagnosed multiple myeloma or as salvage therapy, is considered investigational. Allogeneic and tandem hematopoietic cell transplantation are considered investigational to treat POEMS syndrome.

investigational stance

Tandem autologous HCT — Evidence-based stance

Tandem autologous HCT in newly diagnosed MM

evidence_summary: Randomized controlled trials and a systematic review show tandem autologous HCT can improve overall survival, recurrence-free survival, and complete response rates versus single autologous HCT in newly diagnosed MM, though results across trials are inconsistent due to nonuniform regimens and adherence issues.

Evidence judged sufficient to improve net health outcome in some settings.

Allogeneic HCT — Insufficient evidence for routine use

Allogeneic HCT as initial or salvage therapy in MM

evidence_summary: Nonrandomized and heterogeneous studies report mixed outcomes; nonmyeloablative allo-HCT lowers transplant-related mortality but increases relapse risk; convincing evidence is lacking that allo-HCT improves survival compared with autologous HCT.

Evidence judged insufficient for general improvement in net health outcome.

Autologous HCT — Relapsed/refractory MM

Autologous HCT in relapsed or refractory MM

evidence_summary: Randomized trials and retrospective studies indicate improved overall survival with autologous HCT compared with conventional chemotherapy or continuous lenalidomide plus dexamethasone in relapsed disease; repeat autologous HCT and tandem autologous HCT show survival benefit in selected relapsed/refractory settings.

Evidence sufficient to determine improvement in net health outcome.

Autologous HCT — POEMS syndrome

HCT for POEMS syndrome

evidence_summary: Evidence consists of retrospective cohorts, case reports and series; no RCTs exist due to rarity. For disseminated POEMS syndrome, a chain of evidence and analogy to multiple myeloma suggest autologous HCT improves outcomes and is considered a clinical option or consolidation therapy.

Evidence judged sufficient to improve net health outcome for eligible individuals.

Guideline-based considerations

Professional society recommendations (context for coverage decisions)

guideline_alignment: ASCO, ASTCT/ASBMT, and NCCN recommend offering upfront autologous HCT to eligible individuals with newly diagnosed multiple myeloma (with delayed HCT an option), recommend against routine tandem or allogeneic HCT for all patients but allow tandem or allo-HCT in select high-risk or trial settings, and support repeat HCT in relapse when appropriate; NCCN also recommends collecting enough stem cells for two transplants if tandem or salvage transplant might be considered.

Use these guidelines to inform coverage and authorization decisions.

Medicare NCD: Allogeneic HSCT coverage conditions

Medicare national coverage conditions (as referenced in the policy):

Medicare NCD conditions for allogeneic HSCT: Effective January 2016, allogeneic HSCT for multiple myeloma is covered by Medicare only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or ISS Stage II or III multiple myeloma AND participation in an approved prospective clinical study that meets specified methodological criteria.stage = Durie-Salmon II/III or ISS II/III; participation in qualifying study

Study must control for selection bias and confounders including age, disease duration, disease classification, ISS stage, comorbid conditions, preparative regimen, GVHD prophylaxis, donor type and cell source.

Allogeneic and tandem hematopoietic cell transplantation are designated investigational to treat POEMS syndrome. The policy notes that autologous HCT may be considered medically necessary for disseminated POEMS syndrome, but explicitly classifies both allogeneic and tandem HCT as investigational for this indication.

Routine front-line allogeneic hematopoietic cell transplantation (allo-HCT) is not recommended and is considered investigational/developmental for newly diagnosed multiple myeloma. The evidence from nonrandomized and heterogeneous studies has not shown that allo-HCT improves survival compared with autologous HCT, and professional society guidance (ASTCT/ASBMT) classifies allo-HCT for initial myeloma therapy as developmental or not generally recommended, supporting use primarily in clinical-trial or select high-risk settings.

Medicare does not cover allogeneic hematopoietic stem cell transplantation (HSCT) for multiple myeloma except for beneficiaries who meet specific staging criteria and who are participating in an approved prospective clinical study. Effective January 2016, coverage is limited to beneficiaries with Durie‑Salmon Stage II or III or ISS Stage II or III multiple myeloma and only when enrolled in a qualifying study that meets methodological criteria (including control for selection bias and relevant confounders).

Allogeneic HCT as first-line therapy for newly diagnosed multiple myeloma has not demonstrated superior survival compared with autologous HCT and is therefore considered investigational for initial treatment. Nonmyeloablative approaches reduce transplant‑related mortality but have higher relapse risk, and overall the available evidence is insufficient to support routine upfront allo‑HCT over autologous transplantation.

Available evidence is insufficient to conclude that allogeneic HCT as initial therapy for multiple myeloma improves net health outcomes compared with autologous HCT. Published studies are nonrandomized, heterogeneous in conditioning regimens and patient selection, and show inconsistent outcome reporting; thus routine use of allo‑HCT as first‑line therapy is not supported outside of clinical trials or select circumstances.

CPT and HCPCS Codes

Covered CPT CodesCPTCovered

38230	Bone marrow harvesting for transplantation; allogeneic
38232	Bone marrow harvesting for transplantation; autologous
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
38241	Hematopoietic progenitor cell (HPC); autologous transplantation

Covered HCPCS CodesHCPCSCovered

S2142

Cord blood-derived stem-cell transplantation, allogeneic

S2150

Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition

Authorization, Documentation, and Operational Guidance

Prior Authorization

Prior Authorization Required

Preauthorization is implied for transplant procedures identified by specific CPT/HCPCS codes. Providers should obtain prior authorization when scheduling hematopoietic cell transplantation and supply required documentation to support medical necessity.

A prior authorization request should reference the applicable transplant CPT/HCPCS codes (e.g., 38230, 38232, 38240, 38241; HCPCS S2142, S2150) and include clinical records demonstrating eligibility.

Step Therapy

Sequencing and Guideline-Aligned Prioritization

Autologous HCT is the preferred option after induction for transplant-eligible individuals per guideline recommendations; collect and store enough stem cells for two transplants when tandem or salvage transplant is a consideration. Tandem autologous HCT is an option for individuals who fail to achieve at least a very good partial response after the first transplant or for select high-risk patients. Routine up-front allogeneic HCT is not recommended outside clinical trials.

Collect sufficient graft material when planning for potential tandem or salvage autologous HCT.

Clinical Background and Context

Multiple myeloma and POEMS syndrome are plasma cell disorders for which high‑dose chemotherapy with hematopoietic cell transplantation may be considered. For multiple myeloma, autologous HCT is commonly used as consolidation and a single or second (salvage) autologous transplant may be medically necessary; tandem autologous HCT can be considered when the first transplant does not achieve at least a near‑complete or very good partial response. For POEMS syndrome, autologous HCT may be medically necessary for disseminated disease, while allogeneic and tandem HCT are considered investigational. Allogeneic HCT carries higher treatment‑related morbidity and, based on current evidence, is generally reserved for clinical‑trial or select high‑risk situations.

Key Definitions and Abbreviations

Very good partial response — definition

Very Good Partial Response (VGPR)Serum and urine M‑protein detectable by immunofixation but not on electrophoresis OR >90% reduction in serum M‑protein plus urine M‑protein <100 mg/24 h.

Complete Response (context)Criteria include negative immunofixation on serum and urine, disappearance of soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow aspiration.

Disseminated POEMS (related note)Individuals with disseminated POEMS may have diffuse sclerotic lesions or disseminated bone marrow involvement.

RIC — Reduced‑intensity conditioning

Reduced‑Intensity Conditioning (RIC)Pretransplant use of lower doses of cytotoxic drugs or less intense radiotherapy than traditional myeloablative regimens; intended to reduce treatment‑related morbidity and nonrelapse mortality while allowing graft‑versus‑malignancy effects to develop.

Policy Revision History

2026-03-09policy_approvalLatest

Policy approved; updated with literature review through November 17, 2025 and references added; policy statements unchanged.

2018-04-01annual_review

Annual review with literature update through November 2017; policy statements unchanged.

2019-04-01annual_review

Policy Summary

PayerPremera Bluecross

PolicyHematopoietic Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome

Policy CodePolicy 8.01.17

Change TypeNo material clinical or coverage changes

Effective DateApr 1, 2026

Next Review DateApr 1, 2026

Key ActionObtain preauthorization and provide documentation showing medical necessity criteria are met, including diagnosis, disease severity, and prior treatments.

SourceLink

On This Page

Tandem autologous HCT may be considered when response to first transplant is inadequate (e.g., less than very good partial response) or for select high-risk patients.

Allogeneic HCT should generally be reserved for clinical trials or select high-risk situations; do not use front-line allo-HCT routinely.

Prior Authorization

Medicare Coverage Limited to Qualifying Clinical Studies

Medicare covers allogeneic HSCT for multiple myeloma only for beneficiaries meeting specific staging criteria and who are participating in an approved prospective clinical study under Coverage with Evidence Development (CED). Providers should confirm Medicare coverage criteria and document study participation when applicable.

Medicare coverage applies only to beneficiaries with Durie-Salmon Stage II or III or ISS Stage II or III who are enrolled in an approved prospective clinical study meeting CMS requirements.
Ensure documentation of beneficiary staging and prospective clinical study enrollment is included in the authorization and medical record.

Documentation Required

Required Documentation

Medical records submitted for review must document that medical necessity criteria are met. Incomplete documentation may lead to denial on review.

Documented diagnosis/condition (e.g., multiple myeloma, POEMS) with staging where applicable (Durie-Salmon, ISS).
History and physical examination detailing disease severity and response to prior therapy (including response to induction and prior HCT).
Prior treatments received, including induction regimens, maintenance therapy, and timing/response to any prior HCT.
When requesting tandem or repeat HCT, include rationale (e.g., inadequate response to first transplant, progression-free interval after first HCT).
For Medicare CED cases, include documentation of participation in the approved prospective clinical study and evidence the study meets CMS-specified methodological criteria.

Documentation Required

Documentation Requirements for Medicare CED Studies

A prospective clinical study seeking Medicare coverage under CED must address transplant-specific outcomes and use appropriate methods to control for selection bias and confounding. Providers must include study details and relevant outcome measures in the record to support Medicare coverage.

Study must address acute and chronic graft-versus-host disease (GVHD).
Study must report other transplant-related adverse events.
Study must report overall survival; quality of life is optional but recommended.
Study design must include appropriate statistical techniques to control for selection bias and confounding (age, disease stage/classification, comorbidities, preparative regimen, donor type, cell source, GVHD prophylaxis).
Include documentation of prospective study enrollment, protocol identifier, and how outcomes will be collected and reported when submitting for Medicare consideration.

Denial Risk

Denial Risk for Insufficient Documentation

Failure to provide adequate clinical documentation of diagnosis, staging, severity, prior treatments, or study participation (for Medicare CED) may result in denial of authorization or coverage.

Missing documentation of staging (Durie-Salmon or ISS) or absence of documented prospective study enrollment for Medicare CED cases increases denial risk.
Lack of records showing prior induction therapy, response status, or rationale for tandem/repeat/allo-HCT may lead to payment denial on review.

Spectrum of intensity

RIC regimens range from nearly myeloablative to minimally myeloablative with lymphoablation; intensity is tailored to disease and patient condition.

Chimerism outcomeIndividuals initially show donor cell engraftment and mixed chimerism and most subsequently convert to full‑donor chimerism.

Allogeneic HCT — definition

Allogeneic HCT — basic definitionHematopoietic cell transplantation in which hematopoietic stem cells are obtained from a donor (non‑self) and infused to restore marrow and immune function.

Source and compatibilityDonor cells may be harvested from bone marrow, peripheral blood, or umbilical cord blood; immunologic compatibility (HLA matching) between donor and recipient is critical for success.

Myeloablative vs nonmyeloablativeAllogeneic HCT can be myeloablative or nonmyeloablative (reduced‑intensity); choice affects transplant‑related morbidity and graft‑versus‑tumor effects.

Tandem autologous HCT — definition

Tandem autologous HCT — definitionPlanned sequential autologous hematopoietic cell transplants (two autologous transplants) performed as a planned strategy, often considered for select high‑risk patients or those with suboptimal response to the first transplant.

NCCN operational noteNCCN recommends collecting enough stem cells for two transplants in younger individuals if tandem or salvage transplant might be considered.

Indication for useTandem transplant is an option for individuals who do not achieve at least a very good partial response after the first autologous HCT and those with high‑risk features.

Coverage with Evidence Development (CED) — definition

Coverage with Evidence Development (CED) — conceptA Medicare mechanism requiring participation in an approved prospective clinical study that meets specified methodological criteria as a condition of coverage for certain services.

Study requirements (examples)Studies must use appropriate statistical techniques to control for selection bias and confounders (age, disease duration, ISS stage, comorbidities, conditioning regimen, donor type, cell source).

Outcomes to addressProspective studies should assess graft‑vs‑host disease (acute and chronic), other transplant‑related adverse events, overall survival, and optionally quality of life.

Hematopoietic stem cells — FDA regulation

FDA regulation referenceHuman cells and tissues for implantation, transplantation, or infusion are regulated by FDA CBER under 21 CFR parts 1270 and 1271.

Inclusion of hematopoietic stem cellsHematopoietic stem cells are included within these regulatory requirements.

Regulatory centerRegulation is overseen by the US Food and Drug Administration's Center for Biologics Evaluation and Research (CBER).

Annual review with literature update through November 2018; policy statements unchanged.

2017-04-01annual_review

Annual review with literature update through July 13, 2016 and clinical input; policy statements became less restrictive for treatment of multiple myeloma.

2016-08-01annual_review

Annual review approved July 12, 2016; no changes to policy statements.

2013-11-20update_related_policies

Updated related policies list (added 2.01.91, removed archived policy 8.01.31).

2012-06-12new_policy

New policy created and added to Therapy section, replacing policy 8.01.507.